PAD2 and CitH3 in Pathogenesis of Sepsis-induced ALI

Project: Research project

Project Details


Our proposed research builds upon the premise that PAD2 and CitH3 are important modulators of survival and inflammatory action of macrophages during sepsis. Our study is significant because it addresses critical gaps in knowledge of sepsis-ALI, and can potentially identify molecules that are viable therapeutic targets to reduce the severity and consequences of sepsis-ALI and other multi-organ dysfunction. Our proposed studies combine expertise in cell and molecular biology, animal models, clinical research in sepsis, and chemical biology to elucidate the role of PAD2/CitH3 in the pathogenesis of sepsis-ALI. We have promising data to support the notion that chemical inhibition of PAD2 and antibody sequestration of CitH3 in sepsis have therapeutic benefits. Thus, targeting the PAD2-CitH3 pathway represents a potentially innovative approach that addresses an unmet medical need to treat sepsis-ALI. Several innovative aspects of this project are summarized below:
Effective start/end date9/1/218/31/25


  • University of Michigan (SUBK00014340 Amendment 2 // 5R01HL155116-03)
  • National Heart, Lung, and Blood Institute (SUBK00014340 Amendment 2 // 5R01HL155116-03)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.